Risk Factors for Refractory Diabetic Macular Oedema After Sub-Tenon's Capsule Triamcinolone Acetonide Injection

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2015 Oct 13

PMID 26457195

Citations 5

Authors

Toshiyuki Oshitari

Yuta Kitamura

Sakiko Nonomura

Miyuki Arai

Yoko Takatsuna

Eiju Sato

Takayuki Baba

Shuichi Yamamoto

Affiliations

Soon will be listed here.

Abstract

The purpose of this study is to identify the risk factors for a recurrence or persistence of diabetic macular oedema (DME) after a sub-Tenon's capsule triamcinolone acetonide (STTA) injection. The medical records of 124 patients (124 eyes) treated by STTA were reviewed. The age, sex, HbA1c level, best-corrected visual acuity, central macular thickness, insulin use, pioglitazone use, systemic hypertension, serous retinal detachment, proteinuria, panretinal photocoagulation, microaneurysm photocoagulation (MAPC), subthreshold micropulse diode laser photocoagulation (SMDLP), cataract surgery, and history of vitrectomy were examined by logistic regression analysis. Procedures of MAPC and SMDLP were significantly associated with DME treated with STTA (P = 0.0315, P = 0.04, resp.). However, a history of vitrectomy was found to have significantly fewer recurrences or persistent DME after STTA (P = 0.0464). In conclusion, patients who required combined MAPC or SMDLP with a STTA injection had significantly higher refractoriness to STTA, but postvitrectomy may prevent the recurrence or persistence of DME after STTA injection.

Citing Articles

Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy.

Oshitari T Int J Environ Res Public Health. 2022; 19(1).

PMID: 35010703 PMC: 8744686. DOI: 10.3390/ijerph19010439.

Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion.

Tatsumi T, Oshitari T, Baba T, Takatsuna Y, Yamamoto S Biomed Res Int. 2020; 2020:4529850.

PMID: 33274211 PMC: 7695504. DOI: 10.1155/2020/4529850.

Posterior subtenon infusion of triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation using pattern scan laser for diabetic retinopathy.

Yamada Y, Takamura Y, Matsumura T, Morioka M, Gozawa M, Inatani M Jpn J Ophthalmol. 2018; 62(6):686-692.

PMID: 30328560 DOI: 10.1007/s10384-018-0628-z.

Management of diabetic macular edema in Japan: a review and expert opinion.

Terasaki H, Ogura Y, Kitano S, Sakamoto T, Murata T, Hirakata A Jpn J Ophthalmol. 2017; 62(1):1-23.

PMID: 29210010 DOI: 10.1007/s10384-017-0537-6.

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema.

Shimizu N, Oshitari T, Tatsumi T, Takatsuna Y, Arai M, Sato E Biomed Res Int. 2017; 2017:1747108.

PMID: 28758110 PMC: 5512051. DOI: 10.1155/2017/1747108.

References

Haritoglou C, Kernt M, Neubauer A, Gerss J, Oliveira C, Kampik A . Microaneurysm formation rate as a predictive marker for progression to clinically significant macular edema in nonproliferative diabetic retinopathy. Retina. 2013; 34(1):157-64. DOI: 10.1097/IAE.0b013e318295f6de. View

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R . The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615-25. DOI: 10.1016/j.ophtha.2011.01.031. View

Kern T . Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2008; 2007:95103. PMC: 2216058. DOI: 10.1155/2007/95103. View

Sultan M, Zhou D, Loftus J, Dombi T, Ice K . A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011; 118(6):1107-18. DOI: 10.1016/j.ophtha.2011.02.045. View

Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P . Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997; 16(4):398-406. DOI: 10.1165/ajrcmb.16.4.9115750. View

Oshitari T, Asaumi N, Watanabe M, Kumagai K, Mitamura Y . Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. Vasc Health Risk Manag. 2009; 4(5):1137-40. PMC: 2605323. DOI: 10.2147/vhrm.s3446. View

Nonomura S, Oshitari T, Arai M, Sato E, Takatsuna Y, Baba T . The effect of posterior sub-Tenon's capsule triamcinolone acetonide injection to that of pars plana vitrectomy for diabetic macular edema. Clin Ophthalmol. 2014; 8:825-30. PMC: 4010640. DOI: 10.2147/OPTH.S59849. View

Sakamoto T, Hida T, Tano Y, Negi A, Takeuchi S, Ishibashi T . [Survey of triamcinolone acetonide for ocular diseases in Japan]. Nippon Ganka Gakkai Zasshi. 2008; 111(12):936-45. View

ODoherty M, Dooley I, Hickey-Dwyer M . Interventions for diabetic macular oedema: a systematic review of the literature. Br J Ophthalmol. 2008; 92(12):1581-90. DOI: 10.1136/bjo.2008.144550. View

10.

Takatsuna Y, Yamamoto S, Nakamura Y, Tatsumi T, Arai M, Mitamura Y . Long-term therapeutic efficacy of the subthreshold micropulse diode laser photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2011; 55(4):365-369. DOI: 10.1007/s10384-011-0033-3. View

11.

Chou T, Wu P, Kuo J, Lai C, Kuo C . Relationship of diabetic macular oedema with glycosylated haemoglobin. Eye (Lond). 2008; 23(6):1360-3. DOI: 10.1038/eye.2008.279. View

12.

Ho T, Lai W . Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Ophthalmologica. 2006; 220(5):349-50. DOI: 10.1159/000094630. View

13.

Sears J, Hoppe G . Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci. 2005; 46(11):4336-41. DOI: 10.1167/iovs.05-0565. View

14.

Elman M, Qin H, Aiello L, Beck R, Bressler N, Ferris 3rd F . Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11):2312-8. PMC: 3490003. DOI: 10.1016/j.ophtha.2012.08.022. View

15.

Fong D, Contreras R . Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009; 147(4):583-586.e1. DOI: 10.1016/j.ajo.2008.10.016. View

16.

Do D, Nguyen Q, Boyer D, Schmidt-Erfurth U, Brown D, Vitti R . One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8):1658-65. DOI: 10.1016/j.ophtha.2012.02.010. View

17.

Ohguro N, Okada A, Tano Y . Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2004; 242(5):444-5. DOI: 10.1007/s00417-003-0853-z. View

18.

Qi H, Bi S, Wei S, Cui H, Zhao J . Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res. 2012; 37(12):1136-47. DOI: 10.3109/02713683.2012.705412. View

19.

Klein R, Klein B, Moss S, Cruickshanks K . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995; 102(1):7-16. DOI: 10.1016/s0161-6420(95)31052-4. View

20.

Yau J, Rogers S, Kawasaki R, Lamoureux E, Kowalski J, Bek T . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3):556-64. PMC: 3322721. DOI: 10.2337/dc11-1909. View